As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research grant programs and LLS’s venture philanthropy, the Therapy Acceleration Program (TAP).
A new type of cancer cell that “warrants urgent investigation” has been discovered in childhood leukaemia, and could impact clinical care. Research into new or repurposed treatments that target this new cell type could give hope to children and families worldwide.
